News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase I (World)
GlaxoSmithKline (GSK) Becomes First Drug Firm to Use Apple (AAPL)’s ResearchKit for Clinical Research 7/18/2016
VAXIMM Initiates Phase 1 Translational Study In Glioblastoma With Oral T-Cell Immunotherapy, VXM01 7/12/2016
Akari Therapeutics Receives Positive Opinion For Orphan Drug Designation For Coversin In The European Union For Treatment Of Paroxysmal Nocturnal Hemoglobinuria 7/12/2016
uniQure (QURE) Announces Oral Presentation Of Updated Results For AMT-060 At The World Federation Of Hemophilia (WFH) 2016 World Congress 7/11/2016
China's BeiGene (BGNE) Starts Combination Trial For Two Novel Cancer Drugs 7/7/2016
Scancell (SCNLF) Delays Melanoma Trial 9 to 12 Months to Whip Up New Batch of Cancer Vaccine 7/7/2016
Nanobiotix Reports Successful Results From Phase I/II Trial Of NBTXR3 In Head & Neck Cancer 7/7/2016
Minoryx Therapeutics Initiates Phase 1 Clinical Trial Of MIN-102 7/6/2016
Initiation Of Phase 1 Clinical Study With Novel Immuno-Oncology Candidate Triggers US$10 Million Milestone Payment From AstraZeneca PLC (AZN) 7/6/2016
Heptares Anounces Initiation Of Phase 1 Clinical Study With Novel Immuno-Oncology Candidate Triggers US$10 Million Milestone Payment From AstraZeneca PLC (AZN) 7/6/2016
Lysogene Begins Multi-National Observational Study As It Prepares To Initiate Pivotal Clinical Trial For The Treatment Of Sanfilippo Type A 7/6/2016
First-In-Human Study Of Immbio's Novel Pneumococcal Vaccine Pnubiovax Shows Vaccine To Be Safe And Immunogenic 6/30/2016
PsiOxus Gets Upfront $10 Million, Ties Immuno-Oncology Clinical Pact With Bristol-Myers Squibb (BMY) 6/30/2016
Symphogen Advances Sym015 Into Clinical Development Using Selexis SA SGEs (Selexis Genetic Elements) 6/29/2016
Neuromax Announces Start Phase 1 Clinical Trial Of AQU-005 For The Treatment Of Neuropathic Pain 6/28/2016
Roche (RHHBY) CEO 'Sleeping Much Better' Following Positive News About Three New Drugs 6/23/2016
Scancell (SCNLF) Suspends Dosing in Melanoma Trial Due to Quality Issues 6/17/2016
uniQure (QURE) Presents Clinical Data From Ongoing Phase I/II Study In Hemophilia B Demonstrating 6 Months Of Sustained Increases In Factor IX Activity 6/13/2016
BioTime (BTX)’s Subsidiary Cell Cure Neurosciences Receives DSMB Approval To Start Second Patient Cohort In Clinical Trial For Dry-AMD 6/13/2016
Nordic Nanovector: Pre-Dosing NHL Patients With HH1 Anti-CD37 Antibody Before Betalutin® Increases Its Pharmacokinetic Exposure And Reduces Its Haematological Toxicity 6/10/2016
Galderma Laboratories Trifarotene Development Program Meets Key Milestone For Lamellar Ichthyosis Orphan Disease 6/9/2016
Paradigm Provides Clinical Trial Update 6/9/2016
GenSight Biologics Announces Additional Promising Results Of Its Phase I/II Study With GS010 For The Treatment Of Leber’s Hereditary Optic Neuropathy (LHON) 6/8/2016
ASCO2016: BerGenBio AS Reports First-In-Patient Phase 1 Data For BGB324 In Patients With Myeloid Malignancies At The 2016 American Society Of Clinical Oncology (ASCO) Annual Meeting 6/7/2016
Living Cell Tech's NTCELL Demonstrates Continued Reversal Of Parkinson's Disease 6/7/2016
ASCO2016: Gamida Cell Presents Data From Phase 1/2 Study Of Nicord For High Risk Hematological Malignancies At ASCO 2016 6/6/2016
ASCO2016: VAXIMM Presents Data From Phase I Trial In Pancreatic Cancer With Oral T-Cell Immunotherapy VXM01 At ASCO 2016 Annual Meeting 6/6/2016
ASCO2016: Peloton Therapeutics Presents Clinical Data On First-In-Class Oral HIF-2a Inhibitor In Patients With Advanced Kidney Cancer At 2016 ASCO Annual Meeting 6/6/2016
ASCO2016: MorphoSys AG Presents Updated Clinical Data For MOR202 In Multiple Myeloma And For MOR208 In Non-Hodgkin's Lymphoma At ASCO 2016 6/6/2016
ASCO2016: Aprea Announces Efficacy And Safety Data In High-Grade Serous Ovarian Cancer Patients Treated With Investigational APR-246 Presented At 2016 ASCO Annual Meeting 6/6/2016
ASCO2016: VBL Therapeutics (VBLX) VB-111 Clinical Data Presented At ASCO Demonstrate Significant Increase In Overall Survival In Platinum-Resistant Ovarian Cancer 6/6/2016
Agios (AGIO) Reports Initial Data From Phase I Study Of AG-519 In Healthy Volunteers 6/6/2016
ASCO2016: Cortice Biosciences Announces Presentation Of Results From A Phase I/II Clinical Trial Evaluating TPI 287 For Treatment Of Recurrent Glioblastoma At The Annual Meeting Of The ASCO 6/3/2016
Vectura (VEC.L) Reports Successful Completion Of VR942 Phase I Clinical Study 6/3/2016
FDA Grants Orphan Drug Designation To Debiopharms IAP Inhibitor Debio 1143 In The Treatment Of Ovarian Cancer 6/2/2016
Isofol Medical AB Has Successfully Advanced To The Next Dose Level Of Modufolin In A Phase I/II Clinical Trial In Colorectal Cancer 6/2/2016
MiNA Announces Initiation Of Phase I Clinical Study Of MTL-CEBPA In Patients With Liver Cancer 6/2/2016
PharmaMar Reports Positive Results From The Phase I Study Of Plitidepsin In Combination With Bortezomib And Dexamethasone In Patients With Multiple Myeloma At The 2016 ASCO Annual Meeting 5/19/2016
Nordic Nanovector First Quarter 2016 Results: Strong Progress On All Priorities And Execution On Track 5/19/2016
PharmaMar Announces New Data On Yondelis, Plitidepsin And PM1183 To Be Presented At 2016 ASCO Annual Meeting 5/19/2016
Synthon Advances Clinical Evaluation Of Anti-HER2 ADC SYD985 In An Expanded Cohort Of HER2-Positive Metastatic Breast Cancer Patients 5/18/2016
BioSight Release: Arkin Holdings And Primera Capital Lead An Investment Of $13M In Biosight For An Innovative Treatment Of Acute Leukemia 5/16/2016
BioLineRx And MaRS Innovation Sign Framework Collaboration Agreement 5/16/2016
Regeneus (RGS.AX) Enrollment Complete And Positive Safety In Progenza Trial For Osteoarthritis 5/16/2016
Sensorion To Present Data From Phase Ib Clinical Trial Of SENS-111 At AAO-HNSF Annual Meeting 5/12/2016
Mologen AG (MOLGF.PK): Further Progress In Clinical Studies With Lead Product Lefitolimod In Q1 2016 5/12/2016
AM-Pharma Publishes Safety And Pharmacokinetic Data From Phase I recAP Trial 5/10/2016
MGB Biopharma Limited's Pre-IND Meeting With FDA Provides Clear Guidelines On Further Development Of Oral MGB-BP-3, A Truly Novel Antibiotic Targeting Clostridium Difficile Infections 5/9/2016
Oncolytics Biotech Inc. (ONC.TO) Announces 2016 First Quarter Results 5/6/2016
Regen BioPharma Receives Preliminary Clinical Data From Pan Am Cancer Center Regarding Their HemaXellerate Study In Cancer Patients 5/3/2016
Novogen Limited (NVGN) Provides Update On Development Of Cantrixil 5/2/2016
Cytuvax Reports Interim Results Of The Phase I Clinical Trial With The HBAI20 Hepatitis B Vaccine For Non-Responders 4/29/2016
EBOVAC1 Release: Global Public-Private Partnership Announces Publication Of Positive Phase 1 Data For Ebola Vaccine Regimen In JAMA 4/19/2016
BioSight Completed Treatment Of Patients In Astarabine Phase I/IIa Clinical Trial 4/19/2016
Oncolytics Biotech Inc. (ONC.TO) Collaborators Present REOLYSIN Preclinical Research At The 2016 AACR Annual Meeting 4/18/2016
Merus To Present Interim Clinical Data From Ongoing Phase I/II Clinical Trial Of Its Lead Bispecific Antibody Candidate, MCLA-128, At The AACR 2016 Annual Meeting 4/18/2016
Debiopharm Announces Presentation At AACR Of Non-Clinical Data Relating To Its Targeted Investigational Compound Debio 1347/CH5183284, A Selective FGFR 1,2,3 Inhibitor 4/15/2016
Symphogen Initiates Anti-MET Clinical Program And Presents Pre-Clinical Anti-MET Data At Annual AACR Meeting April 18th In New Orleans 4/12/2016
Hutchison China MediTech (Chi-Med) Initiates First-In-Human Clinical Trial Of Novel PI3K Inhibitor HMPL-689 4/12/2016
Bay Area's Tobira Strikes a $74.5 Million Evogliptin and Cenicriviroc Deal with Dong-A ST 4/11/2016
NMT Pharmaceuticals Singapore Announces Signing Of Licensing Agreement With CAO Pharmaceuticals USA On Anti-Cancer Drug CZ-48 And Initiation Of Phase I Study 4/11/2016
ORYZON Genomics Release: Data On ORY-1001 To Be Presented At The AACR Annual Meeting 2016 In New Orleans 4/11/2016
Galapagos (GLPG.BR) And MorphoSys AG Initiate Phase I Study In Joint Antibody Program MOR106 4/7/2016
Portage Biotech Announcing Results Of Its Annual Shareholder Meeting And Other Corporate Matters 4/7/2016
CANBridge Life Sciences Submits Investigational New Drug Application To Taiwan Food And Drug Administration For CAN-008 Phase I/II Trial In Glioblastoma 4/7/2016
Senhwa Biosciences Release: FDA Approves Clinical Trial Application (CTA) For Phase I/II Clinical Trial Of CX-5461 In Solid Tumors And Breast Cancers 4/1/2016
Janssen To Unveil New Hepatitis B And C Data At The International Liver Congress 2016 Of The European Association For The Study Of The Liver (EASL) 3/30/2016
Oasmia Announces Enrollment Of First Patient In Clinical Study With Docecal, A Novel Formulation Of Docetaxel 3/30/2016
Ambrx, Inc. And Zhejiang Medicine Co. Ltd Initiated ARX788 First-In-Human Phase I Clinical Trial In Cancer Patients 3/22/2016
TauRx Pharma Co-Founder's 30-Year Alzheimer's Quest May Bear Fruit in July 3/21/2016
Isofol Medical AB Share Issue Oversubscribed, Securing Over SEK 39 Million To Strengthen The Ongoing Phase II Clinical Development Program Of Modufolin 3/17/2016
DelMar Pharma Release: FDA Grants Second Orphan Designation For VAL-083 3/15/2016
RedHill Biopharma (RDHL) Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential Of YELIVA In Cholangiocarcinoma Cancer 3/10/2016
Umecrine Cognition Raises New Funds To Support Clinical Development Of Novel Drug Candidate GR3027 For Hepatic Encephalopathy - Phase I Clinical Trial Initiated 3/10/2016
Report Shows High Doses of Experimental Drug Caused Brain Damage in Bial's Botched Trial in France 3/10/2016
BTG plc (BTG.L) Release: New Data From Largest Prospective Study On CroFab For Treatment Of Copperhead Snake Envenomation 3/9/2016
OWC Pharmaceutical Research Corp. Completes Formulation of Cannabinoid-Infused Topical Cream 3/9/2016
AbbVie (ABBV) Coughs Up $595 Million+ for Boehringer Ingelheim's Psoriasis and Crohn’s Drugs 3/8/2016
ImmunoMet Therapeutics Raises $5.2 Million In A Series A Financing 3/8/2016
Parkinson's Disease: Prexton Therapeutics Starts Phase 1 Clinical Trial 3/7/2016
TopiVert To Present First-In-Human Data From Its Phase I Clinical Study With TOP1288 For The Treatment Of Ulcerative Colitis At The Forthcoming 11th Congress Of ECCO In Amsterdam 3/7/2016
Positive Early Stage Pompe Data Allows Sanofi Genzyme (SNY) to Begin Phase III Trial this Summer 3/4/2016
Protalix Biotherapeutics, Inc. (PLX) Presents Positive Six And Twelve Month Interim Clinical Data On PRX-102 For The Treatment Of Fabry Disease At The 12th Annual Worldsymposium 2016 3/3/2016
Prima Biomed (PRR.AX) And WuXi Biologics Announce First Dose Of Chinese-Manufactured Biologic In EU Clinical Trial 3/2/2016
Bial's Fatal Clinical Trial in France Had Already Caused Deaths of Dogs in Earlier Tests 2/29/2016
Benitec (BLT.AX) to Wind Down and Terminate Hep C Program 2/26/2016
Orphan Drug Designation Status for Acerta Pharma Drug Vindicates AstraZeneca PLC (AZN)’s $4 Billion Deal 2/26/2016
Esteve S.A. (Laboratorios Del Dr. Esteve S.A.) And UAB Expand Their Research To Two New Gene Therapies For Sanfilippo B Syndrome And Hunter Syndrome 2/25/2016
Portage Biotech's Biohaven Announces Expedited Development Path For BHV-0223 Following Successful Pre-IND Interaction With FDA 2/25/2016
AstraZeneca PLC (AZN) Continues Its Immuno-Oncology Roll, Durvalumab Gets Breathrough Designation for Bladder Cancer 2/18/2016
BioInvent (BOVNF) Financial Statement 1 January – 31 December 2015 2/17/2016
JHL Biotech Receives Approval From European Authorities To Begin Biosimilar Clinical Trial 2/15/2016
Heptares Announces Positive Results From Phase 1b Clinical Trial With HTL9936, A First-In-Class Selective Muscarinic M1 Receptor Agonist For Improving Cognition In Dementia And Schizophrenia 2/10/2016
DNAtrix, Inc.'s Oncolytic Immunotherapy, DNX-2401, Awarded EU Orphan Medicine Designation For Treating Malignant Brain Tumors 2/9/2016
ERYtech Pharma Announces 2016 Financial Calendar 2/8/2016
Nordic Nanovector To Present At The Swiss-Scandinavian Bio-Business Seminar On 10 February 2016 2/5/2016
Lab Criticized as 'Slow to React' in Bial's Fatal Drug Trial 2/5/2016
Can-Fite BioPharma (CFBI) To Present At BIO CEO & Investor Conference In New York City On February 8, 2016 2/5/2016
ERYtech Pharma To Present At Upcoming Investor Conferences 2/4/2016
Kamada Ltd. (KMDA) Reports 2015 Fourth Quarter And Full Year Financial Results 2/2/2016
Mymetics Announces Discontinuation of the RSV Collaborative Project 1/29/2016
Affimed Therapeutics AG (AFMD) Enters Into Collaboration With Merck & Co. (MRK) To Evaluate AFM13 In Combination With KEYTRUDA (Pembrolizumab) For Patients With Hodgkin Lymphoma 1/25/2016
CARsgen Therapeutics Completes $30 Million Series B Financing 1/25/2016
Oncolytics Biotech Inc. (ONC.TO) Announces First Patients Treated In Phase 1b Study In Advanced Pancreatic Cancer 1/20/2016
Questions Remain as to What Caused the Bial Trial Tragedy in France 1/20/2016
Man in Coma Dies After Bial's Botched Drug Trial in France, Five Remain Hospitalized 1/19/2016
Drugmaker Unnamed as Botched Trial in France Leaves One Patient Brain Dead and Five Hospitalized 1/18/2016
Apogenix Receives First Milestone Payment From CANbridge Licensing Agreement And Signs Amendment To Include Taiwan 1/7/2016
CANbridge Completes Chinese Glioblastoma Biomarker Study For Lead Candidate, CAN008 1/7/2016
Sensorion Receives Approval From The UK Drug Agency To Initiate Clinical Trial Of SENS-218 1/6/2016
Rhythm And Camurus Announce License Agreement For Extended Release Fluidcrystal Setmelanotide 1/5/2016
BioLineRx Ltd. To Present At Biotech Showcase 2016 Conference In San Francisco 1/4/2016
Cellprothera Release: Cellular Regenerative Therapy Greeted By French Minister Of Health 1/4/2016
HUYA Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan 12/22/2015
CSL Behring Submits Marketing Authorization Application To The European Medicines Agency For RViii-SingleChain For Patients With Hemophilia A 12/22/2015
Flamel Technologies (FLML) Announces Positive Interim Results Of A First-In-Man Clinical Trial With MedusaExenatide 12/22/2015
Entia Biosciences Begins Clinical Study Of Proprietary Ergod2 Medical Food Product To Demonstrate Improved Health For The More Than 25 Million Chronic Kidney Disease Sufferers In The U.S. 12/21/2015
DS Biopharma Announces Successful Completion Of A Phase I Safety Study With Bioactive Lipid DS102 Which Is Targeting NASH And IPF 12/18/2015
Akaal Pharma Announces Superior Safety And Comparable Efficacy Of Sphingosine 1-Phosphate Receptor-1 (S1P1) Modulator AKP-11 As Compared To Gilenya (Fingolimod) For The Treatment Of Multiple Sclerosis 12/14/2015
Bayer (BAY) Looks to Become Player in Oncology Treatments 12/14/2015
AstraZeneca PLC (AZN)'s New R&D Approach Involves Diving into the Secretome 12/14/2015
Kadimastem Reached Agreements With The FDA Regarding The Framework Of The Clinical Trials In Humans For The Treatment Of ALS 12/10/2015
CollPlant Reports Positive Interim Trial Results For VergenixSTR, Indicated For The Treatment Of Tendinopathy 12/8/2015
Beigene Presents Clinical Data For BTK Inhibitor BGB-3111 At 57th American Society of Hematology Annual Meeting 12/8/2015
Akari Therapeutics Announces Update From Non-Human Primate Safety Study At International PNH Interest Group 10th Annual Scientific Meeting 12/7/2015
ADC Therapeutics Receives FDA Clearance To Begin Clinical Studies For Its Second Novel Antibody Drug Conjugate ADCT-402 Against Lymphomas And Leukemia 12/4/2015
Celyad Treats First Patient Of Second Cohort In NKG2D CAR T-Cell Phase I Trial 12/1/2015
SELLAS Life Sciences Reports Positive WT1 Cancer Vaccine Clinical Results In Mesothelioma And Acute Myeloid Leukemia (AML) Patients At The Annual International WT1 Conference 11/30/2015
Adocia Announces Positive Phase 1b Results Of BioChaperone Combo In Patients With Type 2 Diabetes 11/25/2015
ESSA Pharma Announces Enrollment Of First Patient In Phase 1/2 Trial 11/25/2015
BioLineRx Ltd. To Host Investor Breakfast In New York On December 3, 2015 11/25/2015
Autifony Therapeutics Initiates Phase I Study Of AUT00206, A Novel Treatment Approach For Schizophrenia 11/25/2015
Novogen Limited (NVGN) Engages Contract Research Organisation To Conduct Cantrixil Phase 1 Clinical Trial 11/24/2015
Cobra Biologics Ltd. Appointed By University of Sheffield To Advance Novel Fusion Protein Technology Into Phase 1 Clinical Trials 11/23/2015
Nitto Denko Corporation (XETRA: ND5.DE)'s ND-L02-S0201:Rnai Anti-Fibrosis Drug For The Treatment Of Liver Fibrosis Granted FDA Fast Track Designation 11/20/2015
AmpliPhi Biosciences Corporation (APHB) Signs Clinical Trial Agreement With University of Adelaide To Conduct A Phase I Trial Of Bacteriophage Therapy For Treating Staphylococcus Aureus Infections 11/19/2015
Allergan (AGN) Release: Positive Phase I/II Interim Data Of Bimatoprost Sustained-Release Implant For IOP Therapy In Glaucoma 11/16/2015
Turing Pharma Initiates Dosing In Phase I Clinical Trial Of TUR-004 For Epileptic Encephalopathies 11/16/2015
DelMar Pharma Presents Data Summarizing The Potential Of VAL-083 As A New Treatment Option For Resistant Cancers 11/13/2015
Novogen Limited (NVGN) Patent Covering Cantrixil And Trilexium Accepted In Australia 11/12/2015
Allergan (AGN) Presents Data At The 2015 American Academy of Ophthalmology Annual Meeting In Las Vegas 11/12/2015
ORYZON Genomics Announces First Patient Dosed In Phase I Extension Cohort Of ORY-1001 11/10/2015
NuCana Presents Exciting Data On Novel Anticancer Agent, NUC-3373, At The AACR-NCI-EORTC Conference In Boston 11/9/2015
Mallinckrodt (MNK) Study Shows Acthar Reduces Disease Activity In Patients With Persistently Active Systemic Lupus Erythematosus 11/9/2015
DS Biopharma Obtains A Granted Patent Covering The Use Of DS102 To Treat Fatty Liver Disorders 11/9/2015
Hutchison China MediTech (Chi-Med) Initiates Sulfatinib U.S. Clinical Trials 11/6/2015
Cynata Engages CRO To Conduct GvHD Clinical Trial 11/5/2015
ESSA Pharma Receives Health Canada Approval To Commence Clinical Development For EPI-506 11/5/2015
Oncolytics Biotech Inc. (ONC.TO) Announces 2015 Third Quarter Results 11/5/2015
DelMar Pharma To Present At The SeeThruEquity Microcap Investor Forum On November 12, 2015 11/5/2015
Adocia Announces Positive Phase 1b Results On The Post-Meal Effect Of BioChaperone Combo In Patients With Type 1 Diabetes 11/4/2015
Debiopharm Presents Positive Preliminary Results From Phase 1 Trials In The Development Of The IAP Inhibitor Debio 1143 At The 27th EORTC-National Cancer Institute-AACR Symposium In Boston 11/3/2015
Jenner Institute at Oxford University Release: Potential New Vaccine Candidate Aims To Block Transmission Of Malaria Parasites 11/2/2015
Hutchison China MediTech (Chi-Med) Release: Completion Of Phase I Clinical Trial Of Novel Syk Inhibitor HMPL-523 For Autoimmune Diseases In Healthy Volunteers 10/30/2015
Astellas (ALPMY) Inititaties Phase 3 Registration Trial Of gilteritinib (ASP2215) In Relapsed Or Refractory Acute Myeloid Leukemia Patients 10/28/2015
The World’s Largest Clinical Study Is Examining the World’s Oldest Wonderdrug, National Institute for Health Research Reveals 10/27/2015
Living Cell Technologies Ltd. Data Shows NTCELL Treatment Has Stopped The Progression Of Parkinsons 10/27/2015
Blaze Bioscience Inc. Announces Presentation At GAC-SC 2015 Conference 10/27/2015
RedHill Biopharma Ltd. (RDHL) Announces Positive Top-Line Results From YELIVA (ABC294640) Phase I Study In Advanced Solid Tumors 10/26/2015
Aprea Presents Preliminary Clinical Phase Ib/II Results In Ovarian Cancer With APR-246 – A ‘First-In-Class’ Compound Reconverting Mutant To Wild-Type P53 Protein 10/23/2015
Hutchison China MediTech (Chi-Med) Release: Proof-Of-Concept Study Of Fruquintinib In Non-Small Cell Lung Cancer Triggers Milestone Payment 10/23/2015
ERYtech Pharma Announces Publication Of Two Articles Describing Clinical Results With ERY-ASP/GRASPA 10/21/2015
Cormorant Pharmaceuticals Release: Decision Taken To Escalate To The Next Dose Level In A Clinical Trial With Humax-IL8 In Patients With Advanced Solid Tumors Ongoing At The National Cancer Institute 10/21/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Phase 1b Study In Advanced Pancreatic Cancer 10/20/2015
First Participants Enrolled In Replicel Life Sciences's Phase 1 Clinical Trial Of Its RCS-01 Dermatology Injectable 10/20/2015
Ability Pharmaceuticals Announces Positive Phase 1/1b Study Results Of ABTL0812 In Cancer Patients With Advanced Solid Tumors 10/20/2015
Protalix Biotherapeutics, Inc. (PLX) Reports Positive Long Term Data On PRX-102 For Fabry Disease 10/19/2015
AstraZeneca PLC (AZN) Halts Two Lung Cancer Drug Combination Trials After Lung Disease Reports 10/13/2015
BeiGene Co.,Ltd Doses First Patient In China With BGB-283 For Solid Tumors 10/12/2015
3SBio Inc. (SSRX) Signs Exclusive Patent License Agreement For ALT-P7, An Antibody-Drug Conjugate Targeting HER2 With Alteogen 10/12/2015
CollPlant Announces Completion Of Patient Recruitment For Clinical Trial Of VergenixFG (Flowable Gel) For The Treatment Of Chronic Wounds 10/7/2015
Ascend Announces Patients With Nodular Basal Cell Carcinoma Receives First Dose Of ASN-002 In Phase 1/2a Study 10/7/2015
Summit Therapeutics Presents Additional Data From Phase Ib Modified Diet Clinical Trial Of SMT C1100 In DMD Patients At WMS 9/30/2015
DelMar Pharmaceuticals To Present Data On The Promising Potential Of VAL-083 In The Treatment Of Pediatric Brain Tumors 9/29/2015
Aduro Biotech (ADRO) Announces Phase 1b Mesothelioma Trial Featured In Spotlight Poster At ESMO/ECC 9/28/2015
RXi Pharmaceuticals (RXII) Granted Patent In China For Lead Clinical Candidate RXI-109 9/28/2015
TiGenix Release: AlloCSC-01 Phase I Data Presented At The Congress Of European Society of Cardiology 9/23/2015
Pharmaxis (PXS.AX) Releases Successful Results Of Phase 1 Clinical Trial For Boehringer Ingelheim Partnered Drug PXS-4728A 9/22/2015
Pluristem Therapeutics (PSTI) and National Institute of Allergy And Infectious Diseases (NIAID) Complete FDA Meeting on PLX-R18 Cells in ARS 9/21/2015
uniQure (QURE) Release: Positive Topline Results Announced From Phase I/II Trial In Sanfilippo B Syndrome Patients Using Uniqure's Novel AAV5-Based Gene Therapy 9/21/2015
BerGenBio AS Release: BGB324 Enhances Immune Checkpoint Inhibitor Efficacy In Preclinical Cancer Models 9/21/2015
Bionomics Limited (BNO.AX) Reports Positive Data From Phase 1 Multiple Ascending Dose Trial Of BNC210 For Anxiety And Depression 9/16/2015
Benitec (BLT.AX) Initiates A Fourth Site In Hepatitis C Clinical Trial 9/16/2015
EnGeneIC Pty Ltd To Initiate U.S. Phase 1 Clinical Study Using Targeted EDV Nanocells To Treat Advanced Glioma Patients 9/16/2015
Transition Therapeutics Inc. (TTH.TO) Announces Fiscal 2015 Financial Results 9/16/2015
Cellular Biomedicine Group (CBMG) To Present CAR-T Phase I Clinical Trial Data For Non Small Cell Lung Cancer And Other Solid Tumors At 5th World Congress On Cancer Therapy 9/16/2015
Glenmark Pharmaceuticals's Bi-Specific Antibody - GBR 1302 To Enter Phase I Trials 9/15/2015
Celyad Announces the Appointment Of Dr. Frederic Lehmann As Vice President Immuno-Oncology 9/15/2015
Replicel Life Sciences Announces Initiation Of Clinical Site And Participant Recruitment For European Skin Aging Study 9/15/2015
Oryx Pharmaceuticals, Inc. Enrolls First Patients In An Additional Phase I Trial With Therapeutic Vaccine Vicoryx To Treat HPV-Associated Cancers In Combination With Standard Chemotherapy 9/15/2015
ProQR Therapeutics B.V. (PRQR) Announces A Proof-Of-Concept Nasal Potential Difference Study Of QR-010 Is Open For Enrollment 9/14/2015
Cellular Biomedicine Group (CBMG) To Release CAR-T For Non-Small Cell Lung Cancer Phase I Clinical Trial Data At 2015 European Cancer Congress 9/14/2015
Merck KGaA (MKGAF.PK), Darmstadt, Germany And Pfizer (PFE) To Present Updates For Avelumab At The European Cancer Congress 2015 9/11/2015
Neovacs SA Confirms Potent And Long-Lasting Biological Activity Of IFNa-Kinoid 4 Years After Patient Dosing In Phase I/IIa Trial 9/9/2015
Protalix Biotherapeutics, Inc. (PLX) Reports Positive Phase I/II Interim Clinical Data On The 1mg/Kg Cohort Of PRX-102 For Fabry Disease 9/9/2015
DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data On VAL-083 In Refractory Glioblastoma Multiforme At GBM2015 9/9/2015
Celsion (CLSN) Updates Clinical Trial Data and Slashes 20% of Workforce 9/9/2015
ORYZON Genomics Achieves Milestone In The Clinical Development Of ORY-1001 9/8/2015
Gordagen Confirms Bioavailability In Phase I Study For Evidence-Based Nutraceuticals 9/8/2015
Glenmark Pharmaceuticals's Novel Monoclonal Antibody GBR 830 To Enter Phase 2 Clinical Studies In Atopic Dermatitis And Celiac Disease In US And Europe 9/3/2015



//-->